Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
- Resource Type
- Article
- Source
- In
Gynecologic Oncology October 2020 159(1):79-87 - Subject
- Language
- ISSN
- 0090-8258